Yahoo Web Search

Search results

    • KRAS inhibitors: The next frontier beckons

      KRAS inhibitors: The next frontier beckons

      Pharmaceutical Technology via Yahoo Finance· 1 day ago

      KRAS G12C inhibitor monotherapies have demonstrated limited clinical efficacy due to primary and acquired resistance mechanisms. Therefore, even if the...

    • Q1 2024 Bio Path Holdings Inc Earnings Call

      Thomson Reuters StreetEvents via Yahoo Finance· 1 day ago

      It is an open-label, two-stage, multi-center study of prexigebersen in combination with decitabine and venetoclax in two cohorts of patients with previously untreated AML and refractory < ...